Table 2 Patients’ background.

From: Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy

Characteristics

Number or median

Percentage or range

Total patients

27

 

Age at diagnosis, years (median)

61

41–75

Clinical stage (number)

IIIC

18

66.7%

IVA

1

3.7%

IVB

8

29.6%

NAC cycle, times (median)

6

3–10

Duration from last NAC to IDS, days (median)

35

23–53

Complete surgery (number)

18

66.7%

Adjuvant chemotherapy (number)

Platinum-based

21

77.8%

Non-platinum based

4

14.8%

No adjuvant therapy

2

7.4%

CA125 level, U/mL (median)

1881

142–17,434

At diagnosis

Presurgery

26

8.2–587

Recurrence (number)

24

88.9%

Death (number)

19

70.3%

  1. NAC neo-adjuvant chemotherapy, IDS interval-debulking surgery.